Artificial cardiac pacemaker

Last updated
Artificial cardiac pacemaker
St Jude Medical pacemaker with ruler.jpg
St. Jude single-lead pacemaker with ruler in cm (released in 2005 [1] [2] )
Specialty Cardiology, electrophysiology

An artificial cardiac pacemaker, commonly referred to as simply a pacemaker, is an implanted medical device that generates electrical pulses delivered by electrodes to one or more of the chambers of the heart. Each pulse causes the targeted chamber(s) to contract and pump blood, [3] thus regulating the function of the electrical conduction system of the heart.

Contents

The primary purpose of a pacemaker is to maintain an even heart rate, either because the heart's natural cardiac pacemaker provides an inadequate or irregular heartbeat, or because there is a block in the heart's electrical conduction system. Modern pacemakers are externally programmable and allow a cardiologist to select the optimal pacing modes for individual patients. Most pacemakers are on demand, in which the stimulation of the heart is based on the dynamic demand of the circulatory system. Others send out a fixed rate of impulses. [4]

A specific type of pacemaker, called an implantable cardioverter-defibrillator, combines pacemaker and defibrillator functions in a single implantable device. [5] Others, called biventricular pacemakers, have multiple electrodes stimulating different positions within the ventricles (the lower heart chambers) to improve their synchronization. [6]

Methods of pacing

An ECG in a person with a single-chamber pacemaker to the atrium. Note the circle around one of the sharp electrical spikes in the position where the P wave would be expected. AtrialPacemakerECG.JPG
An ECG in a person with a single-chamber pacemaker to the atrium. Note the circle around one of the sharp electrical spikes in the position where the P wave would be expected.
An ECG of a person with a dual-chamber pacemaker Duelchamber.JPG
An ECG of a person with a dual-chamber pacemaker

Percussive pacing

Percussive pacing, also known as transthoracic mechanical pacing, is the use of the closed fist, usually on the left lower edge of the sternum over the right ventricle in the vena cava, striking from a distance of 20 – 30 cm to induce a ventricular beat (the British Journal of Anaesthesia suggests this must be done to raise the ventricular pressure to 10–15 mmHg to induce electrical activity). This is an old procedure used only as a life-saving means until an electrical pacemaker is brought to the patient. [7]

Transcutaneous pacing

Transcutaneous pacing (TCP), also called external pacing, is recommended for the initial stabilization of hemodynamically significant bradycardias of all types. The procedure is performed by placing two pacing pads on the patient's chest, either in the anterior/lateral position or the anterior/posterior position. The rescuer selects the pacing rate, and gradually increases the pacing current (measured in mA) until electrical capture (characterized by a wide QRS complex with a tall, broad T wave on the ECG) is achieved, with a corresponding pulse. Pacing artifact on the ECG and severe muscle twitching may make this determination difficult. External pacing should not be relied upon for an extended period of time. It is an emergency procedure that acts as a bridge until transvenous pacing or other therapies can be applied. [8]

Epicardial pacing (temporary)

ECG rhythm strip of a threshold determination in a patient with a temporary (epicardial) ventricular pacemaker. The epicardial pacemaker leads were placed after the patient collapsed during aortic valve surgery. In the first half of the tracing, pacemaker stimuli at 60 beats per minute result in a wide QRS complex with a right bundle branch block pattern. Progressively weaker pacing stimuli are administered, which results in asystole in the second half of the tracing. At the end of the tracing, distortion results from muscle contractions due to a (short) hypoxic seizure. Because decreased pacemaker stimuli do not result in a ventricular escape rhythm, the patient can be said to be pacemaker-dependent and needs a definitive pacemaker. Pacemaker dependent asystole.jpg
ECG rhythm strip of a threshold determination in a patient with a temporary (epicardial) ventricular pacemaker. The epicardial pacemaker leads were placed after the patient collapsed during aortic valve surgery. In the first half of the tracing, pacemaker stimuli at 60 beats per minute result in a wide QRS complex with a right bundle branch block pattern. Progressively weaker pacing stimuli are administered, which results in asystole in the second half of the tracing. At the end of the tracing, distortion results from muscle contractions due to a (short) hypoxic seizure. Because decreased pacemaker stimuli do not result in a ventricular escape rhythm, the patient can be said to be pacemaker-dependent and needs a definitive pacemaker.

Temporary epicardial pacing is used during open heart surgery should the surgical procedure create atrio-ventricular block. The electrodes are placed in contact with the outer wall of the ventricle (epicardium) to maintain satisfactory cardiac output until a temporary transvenous electrode has been inserted. [9]

Transvenous pacing (temporary)

Transvenous pacing, when used for temporary pacing, is an alternative to transcutaneous pacing. A pacemaker wire is placed into a vein, under sterile conditions, and then passed into either the right atrium or right ventricle. The pacing wire is then connected to an external pacemaker outside the body. Transvenous pacing is often used as a bridge to permanent pacemaker placement. It can be kept in place until a permanent pacemaker is implanted or until there is no longer a need for a pacemaker and then it is removed.

Right atrial and right ventricular leads as visualized under x-ray during a pacemaker implant procedure. The atrial lead is the curved one making a U shape in the upper left part of the figure. Fluoroscopy pacemaker leads right atrium ventricle.png
Right atrial and right ventricular leads as visualized under x-ray during a pacemaker implant procedure. The atrial lead is the curved one making a U shape in the upper left part of the figure.

Permanent transvenous pacing

Permanent pacing with an implantable pacemaker involves transvenous placement of one or more pacing electrodes within a chamber, or chambers, of the heart, while the pacemaker is implanted under the skin below the clavicle. The procedure is performed by incision of a suitable vein into which the electrode lead is inserted and passed along the vein, through the valve of the heart, until positioned in the chamber. The procedure is facilitated by fluoroscopy which enables the physician to view the passage of the electrode lead. After satisfactory lodgement of the electrode is confirmed, the opposite end of the electrode lead is connected to the pacemaker generator.

There are three basic types of permanent pacemakers, classified according to the number of chambers involved and their basic operating mechanism: [10]

The pacemaker generator is a hermetically sealed device containing a power source, usually a lithium battery, a sensing amplifier which processes the electrical manifestation of naturally occurring heart beats as sensed by the heart electrodes, the computer logic for the pacemaker and the output circuitry which delivers the pacing impulse to the electrodes.

Most commonly, the generator is placed below the subcutaneous fat of the chest wall, above the muscles and bones of the chest. However, the placement may vary on a case-by-case basis.

The outer casing of pacemakers is so designed that it will rarely be rejected by the body's immune system. It is usually made of titanium, which is inert in the body.

Leadless pacing

Leadless pacemakers are devices that are as small as a capsule and are small enough to allow the generator to be placed within the heart, therefore avoiding the need for pacing leads. [11] As pacemaker leads can fail over time, a pacing system that avoids these components offers theoretical advantages. Leadless pacemakers can be implanted into the heart using a steerable catheter fed into the femoral vein via an incision in the groin. [11]

Basic function

Single-chamber VVIR/AAIR pacemaker Biotronik Philos SR Single-chamber cardiac pacemaker 29.01.21 JM.jpg
Single-chamber VVIR/AAIR pacemaker
Dual-chamber DDDR pacemaker Boston Scientific Altrua 50 Dual-chamber cardiac pacemaker 29.01.21 JM (2).jpg
Dual-chamber DDDR pacemaker

Modern pacemakers usually have multiple functions. The most basic form monitors the heart's native electrical rhythm. When the pacemaker wire or "lead" does not detect heart electrical activity in the chamber – atrium or ventricle – within a normal beat-to-beat time period – most commonly one second – it will stimulate either the atrium or the ventricle with a short low voltage pulse. If it does sense electrical activity, it will hold off stimulating. This sensing and stimulating activity continues on a beat by beat basis and is called "demand pacing". In the case of a dual-chamber device, when the upper chambers have a spontaneous or stimulated activation, the device starts a countdown to ensure that in an acceptable – and programmable – interval, there is an activation of the ventricle, otherwise again an impulse will be delivered.

The more complex forms include the ability to sense and/or stimulate both the atrial and ventricular chambers.

The revised NASPE/BPEG generic code for antibradycardia pacing [12]
IIIIIIIVV
Chamber(s) pacedChamber(s) sensedResponse to sensingRate modulationMultisite pacing
O = NoneO = NoneO = NoneO = NoneO = None
A = AtriumA = AtriumT = TriggeredR = Rate modulationA = Atrium
V = VentricleV = VentricleI = InhibitedV = Ventricle
D = Dual (A+V)D = Dual (A+V)D = Dual (T+I)D = Dual (A+V)

From this the basic ventricular "on demand" pacing mode is VVI or with automatic rate adjustment for exercise VVIR – this mode is suitable when no synchronization with the atrial beat is required, as in atrial fibrillation. The equivalent atrial pacing mode is AAI or AAIR which is the mode of choice when atrioventricular conduction is intact but the sinoatrial node of the natural pacemaker is unreliable – sinus node disease (SND) or sick sinus syndrome. Where the problem is atrioventricular block (AVB) the pacemaker is required to detect (sense) the atrial beat and after a normal delay (0.1–0.2 seconds) trigger a ventricular beat, unless it has already happened – this is VDD mode and can be achieved with a single pacing lead with electrodes in the right atrium (to sense) and ventricle (to sense and pace). These modes AAIR and VDD are unusual in the US but widely used in Latin America and Europe. [13] [14] The DDDR mode is most commonly used as it covers all the options though the pacemakers require separate atrial and ventricular leads and are more complex, requiring careful programming of their functions for optimal results.

Automatic pacemakers are designed to be over-ridden by the heart's natural rate at any moment that it gets back to a non-pathologic normal sinus rhythm and can reinitiate influencing the electric activity in the heart when the pathologic event happens again. [15] A "ventricular-demand pacemaker" produces a narrow vertical spike on the ECG, just before a wide QRS. The spike of an "atrial-demand pacemaker" appears just before the P wave. [16]

Comparably, a Triggered Pacemaker is activated immediately after an electrical activity is commenced in the heart tissue by itself. A "ventricular triggered pacemaker" produces the impulse just after a pulse is created in the ventricular tissue and it appears as a simultaneous spike with QRS. An "atrial triggered pacemaker" is the mode in which an impulse is produced immediately after an electrical event in the atrium. It appears as a discharge following the p wave but prior to the QRS which is commonly widened. [17]

Biventricular pacing

Three leads can be seen in this example of a cardiac resynchronization device: a right atrial lead (solid black arrow), a right ventricular lead (dashed black arrow), and a coronary sinus lead (red arrow). The coronary sinus lead wraps around the outside of the left ventricle, enabling pacing of the left ventricle. Note that the right ventricular lead in this case has two thickened aspects that represent conduction coils and that the generator is larger than typical pacemaker generators, demonstrating that this device is both a pacemaker and a cardioverter-defibrillator, capable of delivering electrical shocks for dangerously fast abnormal ventricular rhythms. Cardiac resynchronisation therapy.png
Three leads can be seen in this example of a cardiac resynchronization device: a right atrial lead (solid black arrow), a right ventricular lead (dashed black arrow), and a coronary sinus lead (red arrow). The coronary sinus lead wraps around the outside of the left ventricle, enabling pacing of the left ventricle. Note that the right ventricular lead in this case has two thickened aspects that represent conduction coils and that the generator is larger than typical pacemaker generators, demonstrating that this device is both a pacemaker and a cardioverter-defibrillator, capable of delivering electrical shocks for dangerously fast abnormal ventricular rhythms.

Cardiac resynchronization therapy (CRT) is used for people with heart failure in whom the left and right ventricles do not contract simultaneously (ventricular dyssynchrony), which occurs in approximately 25–50% of heart failure patients. To achieve CRT, a biventricular pacemaker (BVP) is used, which can pace both the septal and lateral walls of the left ventricle. By pacing both sides of the left ventricle, the pacemaker can resynchronize the ventricular contractions.

CRT devices have at least two leads, one passing through the vena cava and the right atrium into the right ventricle to stimulate the septum, and another passing through the vena cava and the right atrium and inserted through the coronary sinus to pace the epicardial wall of the left ventricle. Often, for patients in normal sinus rhythm, there is also a lead in the right atrium to facilitate synchrony with the atrial contraction. Thus, the timing between the atrial and ventricular contractions, as well as between the septal and lateral walls of the left ventricle can be adjusted to achieve optimal cardiac function.

CRT devices have been shown to reduce mortality and improve quality of life in patients with heart failure symptoms; a LV ejection fraction less than or equal to 35% and QRS duration on EKG of 120 ms or greater. [18] [19]

Biventricular pacing alone is referred to as CRT-P (for pacing). For selected patients at risk of arrhythmias, CRT can be combined with an implantable cardioverter-defibrillator (ICD): such devices, known as CRT-D (for defibrillation), also provide effective protection against life-threatening arrhythmias. [20]

Conduction System Pacing

Conventional placement of ventricular leads in or around the tip or apex of the right ventricle, or RV apical pacing, can have negative effects on heart function. It has been associated with increased risk of atrial fibrillation, heart failure, weakening of the heart muscle and potentially shorter life expectancy. His bundle pacing (HBP) leads to a more natural or perfectly natural ventricular activation and has generated strong research and clinical interest. By stimulating the His–Purkinje fiber network directly with a special lead and placement technique, HBP causes a synchronized and therefore more effective ventricular activation and avoids long-term heart muscle disease. HBP in some cases can also correct bundle branch block patterns. [21] [22]

Advancements in function

Posteroanterior and lateral chest radiographs of a pacemaker with normally located leads in the right atrium (white arrow) and right ventricle (black arrowhead), respectively X-ray of pacemaker with right atrial and ventricular lead.jpg
Posteroanterior and lateral chest radiographs of a pacemaker with normally located leads in the right atrium (white arrow) and right ventricle (black arrowhead), respectively

A major step forward in pacemaker function has been to attempt to mimic nature by utilizing various inputs to produce a rate-responsive pacemaker using parameters such as the QT interval, pO2 – pCO2 (dissolved oxygen or carbon dioxide levels) in the arterial-venous system, physical activity as determined by an accelerometer, body temperature, ATP levels, adrenaline, etc. Instead of producing a static, predetermined heart rate, or intermittent control, such a pacemaker, a 'Dynamic Pacemaker', could compensate for both actual respiratory loading and potentially anticipated respiratory loading. The first dynamic pacemaker was invented by Anthony Rickards of the National Heart Hospital, London, UK, in 1982. [23]

Dynamic pacemaking technology could also be applied to future artificial hearts. Advances in transitional tissue welding would support this and other artificial organ/joint/tissue replacement efforts. Stem cells may be of interest in transitional tissue welding.[ citation needed ]

Many advancements have been made to improve the control of the pacemaker once implanted. Many of these have been made possible by the transition to microprocessor controlled pacemakers. Pacemakers that control not only the ventricles but the atria as well have become common. Pacemakers that control both the atria and ventricles are called dual-chamber pacemakers. Although these dual-chamber models are usually more expensive, timing the contractions of the atria to precede that of the ventricles improves the pumping efficiency of the heart and can be useful in congestive heart failure.

Rate responsive pacing allows the device to sense the physical activity of the patient and respond appropriately by increasing or decreasing the base pacing rate via rate response algorithms.

The DAVID trials [24] have shown that unnecessary pacing of the right ventricle can exacerbate heart failure and increases the incidence of atrial fibrillation. The newer dual-chamber devices can keep the amount of right ventricle pacing to a minimum and thus prevent worsening of the heart disease.

Considerations

Insertion

A pacemaker may be implanted whilst a person is awake using local anesthetic to numb the skin with or without sedation, or asleep using a general anesthetic. [25] An antibiotic is usually given to reduce the risk of infection. [25] Pacemakers are generally implanted in the front of the chest in the region of the left or right shoulder. The skin is prepared by clipping or shaving any hair over the implant site before cleaning the skin with a disinfectant such as chlorhexidine. An incision is made below the collar bone and a space or pocket is created under the skin to house the pacemaker generator. This pocket is usually created just above the pectoralis major muscle (prepectoral), but in some cases the device may be inserted beneath the muscle (submuscular). [26] The lead or leads are fed into the heart through a large vein guided by X-ray imaging (fluoroscopy). The tips of the leads may be positioned within the right ventricle, the right atrium, or the coronary sinus, depending on the type of pacemaker required. [25] Surgery is typically completed within 30 to 90 minutes. Following implantation, the surgical wound should be kept clean and dry until it has healed. Some movements of the shoulder within a few weeks of insertion carry a risk of dislodging the pacemaker leads. [25]

The batteries within a pacemaker generator typically last 5 to 10 years. When the batteries are nearing the end of life, the generator is replaced in a procedure that is usually simpler than a new implant. Replacement involves making an incision to remove the existing device, disconnecting the leads from the old device and reconnecting them to a new generator, reinserting the new device and closing the skin. [25]

Periodic pacemaker checkups

Two types of remote monitoring devices used by pacemaker patients PaceMakerRemoteMonitoringDevicesTwoKinds.jpg
Two types of remote monitoring devices used by pacemaker patients

Once the pacemaker is implanted, it is periodically checked to ensure the device is operational and performing appropriately; the device can be checked as often as is deemed necessary. Routine pacemaker checks are typically done in-office every six months, though will vary depending upon patient/device status and remote monitoring availability. Newer pacemaker models can also be interrogated remotely, with the patient transmitting their pacemaker data using a transmitter at home connected to a cellular telephone network.

During in-office follow-up, diagnostic tests may include:

  • Sensing: the ability of the device to "see" intrinsic cardiac activity (atrial and ventricular depolarization).
  • Impedance: A test to measure lead integrity. Large and/or sudden increases in impedance can indicate a lead fracture, while large and/or sudden decreases in impedance can be caused by insulation failure.
  • Threshold amplitude: The minimum voltage (generally in hundredths of volts) required in order to pace the atrium or ventricle connected to the lead.
  • Threshold duration: The time that the device requires at the preset amplitude to reliably pace the atrium or ventricle connected to the lead.
  • Percentage of pacing: The percentage of time that the pacemaker has been actively pacing since the previous device interrogation, which shows how dependent the patient is on the device.
  • Estimated battery life at current rate: As modern pacemakers are "on-demand" and only pace when necessary, battery lifespan is affected by how much the pacemaker is utilized. Other factors affecting battery life include programmed output and algorithms (features) that use battery power.
  • Any events that were stored since the last follow-up, in particular arrhythmias such as atrial fibrillation. These are typically stored based on specific criteria set by the physician and specific to the patient. Some devices have the availability to display intracardiac electrograms showing the onset of an event as well as the event itself, which helps to diagnose its cause or origin.

Magnetic fields, MRIs, and other lifestyle issues

A patient's lifestyle is usually not modified to any great degree after the insertion of a pacemaker. There are a few activities that are unwise, such as full-contact sports and exposure of the pacemaker to intense magnetic fields.

The pacemaker patient may find that some types of everyday actions need to be modified. For instance, the shoulder harness of a vehicle seatbelt may be uncomfortable if it falls across the pacemaker insertion site. Women will not be able to wear bras for a while after the operation, and later might have to wear bras with wide shoulder straps.

For some sports and physical activities, special pacemaker protection can be worn to prevent possible injuries, or damage to the pacemaker leads.

Pacemakers may be affected by magnetic or electromagnetic fields, and ionising and acoustic radiation. However, a 2013 study found that "The overall risk of clinically significant adverse events related to EMI (electromagnetic interference) in recipients of CIEDs (cardiovascular implantable electronic devices) is very low. Therefore, no special precautions are needed when household appliances are used. Environmental and industrial sources of EMI are relatively safe when the exposure time is limited and distance from the CIEDs is maximized. The risk of EMI-induced events is highest within the hospital environment." [27] The study lists and tabulates many sources of interference, and many different potential effects: damage to circuitry, asynchronous pacing, etc. Some sources of hazard in older devices have been eliminated in newer ones.

Activities involving strong magnetic fields should be avoided. This includes activities such as arc welding with certain types of equipment, [28] and maintaining heavy equipment that may generate strong magnetic fields. Some medical procedures, particularly magnetic resonance imaging (MRI), involve very strong magnetic fields or other conditions that may damage pacemakers.

However, many modern pacemakers are specified to be MR conditional or MRI conditional, safe to use during MRI subject to certain conditions. [29] The first to be so specified was the Medtronic Revo MRI SureScan, approved by the US FDA in February 2011, [30] which was the first to be specified as MR conditional. [31] [32] There are several conditions to use of MR Conditional pacemakers, including certain patients' qualifications and scan settings. An MRI conditional device has to have MRI settings enabled before a scan, and disabled afterwards. [33]

As of 2014 the five most commonly used cardiac pacing device manufacturers (covering more than 99% of the US market) made FDA-approved MR-conditional pacemakers. [34] The use of MRI may be ruled out by the patient having an older, non-MRI Conditional pacemaker, or by having old pacing wires inside the heart, no longer connected to a pacemaker.

A 2008 US study found [35] that the magnetic field created by some headphones used with portable music players or cellphones may cause interference if placed very close to some pacemakers.

In addition, according to the American Heart Association, some home devices have the potential to occasionally inhibit a single beat. Cellphones do not seem to damage pulse generators or affect how the pacemaker works. [36] It is recommended that objects containing magnets, or generating a significant magnetic field, should not be in close proximity to a pacemaker. Induction cooktops, in particular, can pose a risk. [37]

Before medical procedures, the patient should inform all medical personnel that they have a pacemaker. Having a pacemaker does not imply that a patient requires the use of antibiotics to be administered before procedures such as dental work. [38]

End-of-life care and pacemaker deactivation

A panel of the Heart Rhythm Society, a US specialist organization based in Washington, DC, deemed that it was legal and ethical to honor requests by patients, or by those with legal authority to make decisions for patients, to deactivate implanted cardiac devices. Lawyers say that the legal situation is similar to removing a feeding tube, though as of 2010 there was no legal precedent involving pacemakers in the United States. A patient in many jurisdictions (including the US) is deemed to have a right to refuse or discontinue treatment, including a pacemaker that keeps them alive. Physicians have a right to refuse to turn it off, but are advised by the HRS panel that they should refer the patient to a physician who will. [39] [40] Some patients consider that hopeless, debilitating conditions, such as severe strokes or late-stage dementia, can cause so much suffering that they would prefer not to prolong their lives with supportive measures. [41]

Privacy and security

Security and privacy concerns have been raised with pacemakers that allow wireless communication. Unauthorized third parties may be able to read patient records contained in the pacemaker, or reprogram the devices, as has been demonstrated by a team of researchers. [42] The demonstration worked at short range; they did not attempt to develop a long range antenna. The proof of concept exploit helps demonstrate the need for better security and patient alerting measures in remotely accessible medical implants. [42] In response to this threat, Purdue University and Princeton University researchers have developed a prototype firewall device, called MedMon, which is designed to protect wireless medical devices such as pacemakers and insulin pumps from attackers. [43]

Complications

Ultrasound showing non capture of a pacemaker [44]

Complications from having surgery to implant a pacemaker are uncommon (each 1-3% approximately), but could include: infection where the pacemaker is implanted or in the bloodstream; allergic reaction to the dye or anesthesia used during the procedure; swelling, bruising or bleeding at the generator site, or around the heart, especially if the patient is taking blood thinners, elderly, of thin frame or otherwise on chronic steroid use. [45]

A possible complication of dual-chamber artificial pacemakers is 'pacemaker-mediated tachycardia' (PMT), a form of reentrant tachycardia. In PMT, the artificial pacemaker forms the anterograde (atrium to ventricle) limb of the circuit and the atrioventricular (AV) node forms the retrograde limb (ventricle to atrium) of the circuit. [46] Treatment of PMT typically involves reprogramming the pacemaker. [46]

Another possible complication is "pacemaker-tracked tachycardia," where a supraventricular tachycardia such as atrial fibrillation or atrial flutter is tracked by the pacemaker and produces beats from a ventricular lead. [47] This is becoming exceedingly rare as newer devices are often programmed to recognize supraventricular tachycardias and switch to non-tracking modes. [48]

It is important to consider leads as a potential nidus for thromboembolic events. The leads are small-diameter wires from the pacemaker to the implantation site in the heart muscle, and are usually placed intravenously through the subclavian vein in order to access the right atrium. Placing a foreign object within the venous system in such a manner may disrupt blood-flow and allow for thrombus formation. Therefore, patients with pacemakers may need to be placed on anti-coagulation therapy to avoid potential life-threatening thrombosis or embolus. [49] [50]

These leads may also damage the tricuspid valve leaflets, either during placement or through wear and tear over time. This can lead to tricuspid regurgitation and right-sided heart failure, which may require tricuspid valve replacement. [51]

Sometimes leads will need to be removed. The most common reason for lead removal is infection; however, over time, leads can degrade due to a number of reasons such as lead flexing. [52] Changes to the programming of the pacemaker may overcome lead degradation to some extent. However, a patient who has several pacemaker replacements over a decade or two in which the leads were reused may require lead replacement surgery.

Lead replacement may be done in one of two ways. Insert a new set of leads without removing the current leads (not recommended as it provides additional obstruction to blood flow and heart valve function) or remove the current leads and then insert replacements. The lead removal technique will vary depending on the surgeon's estimation of the probability that simple traction will suffice to more complex procedures. Leads can normally be disconnected from the pacemaker easily, which is why device replacement usually entails simple surgery to access the device and replace it by simply unhooking the leads from the device to replace and hooking the leads to the new device. The possible complications, such as perforation of the heart wall, come from removing the lead{s} from the patient's body.

The free end of a pacemaker lead is actually implanted into the heart muscle with a miniature screw or anchored with small plastic hooks called tines. The longer the leads have been implanted (starting from a year or two), the more likely that they will have additional attachments to the patient's body at various places in the pathway from device to heart muscle, since the body tends to incorporate foreign devices into tissue. In some cases, for a lead that has been inserted for a short amount of time, removal may involve simple traction to pull the lead from the body. Removal in other cases is typically done with a laser or cutting device which threads like a cannula with a cutting edge over the lead and is moved down the lead to remove any organic attachments with tiny cutting lasers or similar device. [53] [54]

Pacemaker lead malposition in various locations has been described in the literature. Treatment varies, depending on the location of the pacer lead and symptoms. [55]

Another possible complication called twiddler's syndrome occurs when a patient manipulates the pacemaker and causes the leads to be removed from their intended location and causes possible stimulation of other nerves.

Overall life expectancy with pacemakers is excellent, and mostly depends upon underlying diseases, presence of atrial fibrillation, age and sex at the time of first implantation. [56]

Other devices

Sometimes devices resembling pacemakers, called implantable cardioverter-defibrillators (ICDs) are implanted. These devices are often used in the treatment of patients at risk from sudden cardiac death. An ICD has the ability to treat many types of heart rhythm disturbances by means of pacing, cardioversion, or defibrillation. Some ICD devices can distinguish between ventricular fibrillation and ventricular tachycardia (VT), and may try to pace the heart faster than its intrinsic rate in the case of VT, to try to break the tachycardia before it progresses to ventricular fibrillation. This is known as fast-pacing, overdrive pacing, or anti-tachycardia pacing (ATP). ATP is only effective if the underlying rhythm is ventricular tachycardia, and is never effective if the rhythm is ventricular fibrillation.

NASPE / BPEG Defibrillator (NBD) code – 1993 [57]
IIIIIIIV
Shock chamberAntitachycardia pacing chamberTachycardia detectionAntibradycardia pacing chamber
O = NoneO = NoneE = ElectrogramO = None
A = AtriumA = AtriumH = HemodynamicA = Atrium
V = VentricleV = VentricleV = Ventricle
D = Dual (A+V)D = Dual (A+V)D = Dual (A+V)
Short form of the NASPE/BPEG Defibrillator (NBD) code [57]
ICD-SICD with shock capability only
ICD-BICD with bradycardia pacing as well as shock
ICD-TICD with tachycardia (and bradycardia) pacing as well as shock

History

In 1958, Arne Larsson (1915-2001) became the first person to receive an implantable pacemaker. He had 26 devices during his life and campaigned for other patients needing pacemakers. Arne Larsson.jpg
In 1958, Arne Larsson (1915–2001) became the first person to receive an implantable pacemaker. He had 26 devices during his life and campaigned for other patients needing pacemakers.

Origin

In 1889, John Alexander MacWilliam reported in the British Medical Journal (BMJ) of his experiments in which application of an electrical impulse to the human heart in asystole caused a ventricular contraction and that a heart rhythm of 60–70 beats per minute could be evoked by impulses applied at spacings equal to 60–70/minute. [58]

In 1926, Mark C Lidwill of the Royal Prince Alfred Hospital of Sydney, supported by physicist Edgar H. Booth of the University of Sydney, devised a portable apparatus which "plugged into a lighting point" and in which "One pole was applied to a skin pad soaked in strong salt solution" while the other pole "consisted of a needle insulated except at its point, and was plunged into the appropriate cardiac chamber". "The pacemaker rate was variable from about 80 to 120 pulses per minute, and likewise the voltage variable from 1.5 to 120 volts". [59] In 1928, the apparatus was used to revive a stillborn infant at Crown Street Women's Hospital in Sydney, whose heart continued "to beat on its own accord", "at the end of 10 minutes" of stimulation. [60] [61]

In 1932, American physiologist Albert Hyman, with the help of his brother, described an electro-mechanical instrument of his own, powered by a spring-wound hand-cranked motor. Hyman himself referred to his invention as an "artificial pacemaker", the term continuing in use to this day. [62] [63]

An apparent hiatus in the publication of research conducted between the early 1930s and World War II may be attributed to the public perception of interfering with nature by "reviving the dead". [64] For example, "Hyman did not publish data on the use of his pacemaker in humans because of adverse publicity, both among his fellow physicians, and due to newspaper reporting at the time. Lidwell may have been aware of this and did not proceed with his experiments in humans". [61]

Transcutaneous

In 1950, Canadian electrical engineer John Hopps designed and built the first external pacemaker based upon observations by cardio-thoracic surgeons Wilfred Gordon Bigelow and John Callaghan at Toronto General Hospital. [65] The device was first tested on a dog at the University of Toronto's Banting Institute. [66] A substantial external device using vacuum tube technology to provide transcutaneous pacing, it was somewhat crude and painful to the patient in use and, being powered from an AC wall socket, carried a potential hazard of electrocution of the patient and inducing ventricular fibrillation. [67]

A number of innovators, including Paul Zoll, made smaller but still bulky transcutaneous pacing devices from 1952 using a large rechargeable battery as the power supply. [68]

In 1957, William L. Weirich published the results of research performed at the University of Minnesota. These studies demonstrated the restoration of heart rate, cardiac output and mean aortic pressures in animal subjects with complete heart block through the use of a myocardial electrode. [69]

In 1958 Colombian doctor Alberto Vejarano Laverde and Colombian electrical engineer Jorge Reynolds Pombo constructed an external pacemaker, similar to those of Hopps and Zoll, weighing 45 kg and powered by a 12 volt car lead–acid battery, but connected to electrodes attached to the heart. This apparatus was successfully used to sustain a 70-year-old priest, Gerardo Florez. [70]

The development of the silicon transistor and its first commercial availability in 1956 was the pivotal event that led to the rapid development of practical cardiac pacemaking. [71]

Wearable

In 1958, engineer Earl Bakken of Minneapolis, Minnesota, produced the first wearable external pacemaker for a patient of C. Walton Lillehei. This transistorized pacemaker, housed in a small plastic box, had controls to permit adjustment of pacing heart rate and output voltage and was connected to electrode leads which passed through the skin of the patient to terminate in electrodes attached to the surface of the myocardium of the heart.

In the UK in the 1960s, Lucas Engineering in Birmingham was asked by Mr Abrams of The Queen Elizabeth Hospital to produce a prototype for a transistorised replacement for the electro-mechanical product. The team was headed by Roger Nolan, an engineer with the Lucas Group Research Centre. Nolan designed and created the first blocking oscillator and transistor-powered pacemaker. This pacemaker was worn on a belt and powered by a rechargeable sealed battery, enabling users to live a more-normal life.

One of the earliest patients to receive this Lucas pacemaker device was a woman in her early 30s. The operation was carried out in 1964 by South African cardiac surgeon Alf Gunning, [72] [73] a student of Christiaan Barnard. This pioneering operation took place under the guidance of cardiac consultant Peter Sleight at the Radcliffe Infirmary in Oxford and his cardiac research team at St George's Hospital in London. [74] [75]

Implantable

Illustration of implanted cardiac pacemaker showing locations of cardiac pacemaker leads PPM.png
Illustration of implanted cardiac pacemaker showing locations of cardiac pacemaker leads

The first clinical implantation into a human of a fully implantable pacemaker was on October 8, 1958, [76] at the Karolinska Institute in Solna, Sweden, using a pacemaker designed by inventor Rune Elmqvist and surgeon Åke Senning (in collaboration with Elema-Schönander AB, later Siemens-Elema AB), connected to electrodes attached to the myocardium of the heart by thoracotomy. The device failed after three hours. A second device was then implanted which lasted for two days. The world's first implantable pacemaker patient, Arne Larsson, went on to receive 26 different pacemakers during his lifetime. He died in 2001, at the age of 86, outliving the inventor and the surgeon. [77]

In 1959, temporary transvenous pacing was first demonstrated by Seymour Furman and John Schwedel, whereby the catheter electrode was inserted via the patient's basilic vein. [78]

In February 1960, an improved version of the Swedish Elmqvist design was implanted by Doctors Orestes Fiandra and Roberto Rubio in the Casmu 1 Hospital of Montevideo, Uruguay. This pacemaker, the first implanted in the Americas, lasted until the patient died of other ailments, nine months later. The early Swedish-designed devices used batteries recharged by an induction coil from the outside.

Implantable pacemakers constructed by engineer Wilson Greatbatch entered use in humans from April 1960 following extensive animal testing. The Greatbatch innovation varied from the earlier Swedish devices in using primary cells (a mercury battery) as the energy source. The first patient lived for a further 18 months.

The first use of transvenous pacing in conjunction with an implanted pacemaker was by Parsonnet in the United States, [79] [80] [81] Lagergren in Sweden [82] [83] and Jean-Jacques Welti in France [84] in 1962–63. The transvenous, or pervenous, procedure involved incision of a vein into which was inserted the catheter electrode lead under fluoroscopic guidance, until it was lodged within the trabeculae of the right ventricle. This became the method of choice by the mid-1960s.

Cardiothoracic surgeon Leon Abrams and medical engineer Ray Lightwood developed and implanted the first patient-controlled variable-rate heart pacemaker in 1960 at the University of Birmingham. The first implant took place in March 1960, with two further implants the following month. These three patients made good recoveries and returned to a high quality of life. By 1966, 56 patients had undergone implantation with one surviving for over 5+1⁄2 years. [85] [86]

Lithium battery

The first lithium-iodide cell-powered pacemaker. Invented by Anthony Adducci and Art Schwalm. Cardiac Pacemakers Inc. 1972 Cardiac pacer with sold-state power source.jpg
The first lithium-iodide cell-powered pacemaker. Invented by Anthony Adducci and Art Schwalm. Cardiac Pacemakers Inc. 1972

The preceding implantable devices all suffered from the unreliability and short lifetime of the available primary cell technology, mainly the mercury battery. In the late 1960s, several companies, including ARCO in the US, developed isotope-powered pacemakers, but this development was overtaken by the development in 1971 of the lithium iodide cell by Wilson Greatbatch. [88] Lithium-iodide or lithium anode cells became the standard for pacemaker designs.

A further impediment to the reliability of the early devices was the diffusion of water vapor from body fluids through the epoxy resin encapsulation, affecting the electronic circuitry. This phenomenon was overcome by encasing the pacemaker generator in a hermetically sealed metal case, initially by Telectronics of Australia in 1969, followed by Cardiac Pacemakers, Inc. of St. Paul, Minnesota in 1972. This technology, using titanium as the encasing metal, became the standard by the mid-1970s.

On July 9, 1974, Manuel A. Villafaña and Anthony Adducci, the founders of Cardiac Pacemakers, Inc. (Guidant), manufactured the world's first pacemaker with a lithium anode and a lithium-iodide electrolyte solid-state battery. Lithium-iodide or lithium anode cells increased the life of pacemakers from one year to as long as eleven years, and has become the standard for pacemaker designs. They began designing and testing their implantable cardiac pacemaker powered by a new longer-life lithium battery in 1971. The first patient to receive a CPI pacemaker emerged from surgery in June 1973. [87] [89]

Liza Morton was fitted with an implantable pacemaker at 11 days old in 1978, at Glasgow’s Yorkhill hospital, Scotland. She was the youngest baby at the time [90] [91]

Intra-cardial

In 2013, several firms announced devices that could be inserted via a leg catheter rather than invasive surgery. The devices are roughly the size and shape of a pill, much smaller than the size of a traditional pacemaker. Once implanted, the device's prongs contact the muscle and stabilize heartbeats. Development of this type of device was continuing. [92] In November 2014, Bill Pike of Fairbanks, Alaska, received a Medtronic Micra pacemaker in Providence St Vincent Hospital in Portland, Oregon. D. Randolph Jones was the EP doctor. Also in 2014, St. Jude Medical Inc. announced the first enrollments in the company's leadless Pacemaker Observational Study evaluating the Nanostim leadless pacing technology. The Nanostim pacemaker received European CE marking in 2013. Post-approval implant trials were carried out in Europe. [93] The European study was stopped after reports of six perforations that led to two patient deaths. After investigations, St Jude Medical restarted the study. [94] In the United States, this therapy had not been approved by the FDA as of 2014. [95] While the St Jude Nanostim and the Medtronic Micra are single-chamber pacemakers, it was anticipated that leadless dual-chamber pacing for patients with atrioventricular block would become possible with further development. [96]

Reusable pacemakers

Worldwide each year, in a simple procedure to avoid explosions, thousands of pacemakers are removed from bodies to be cremated. Pacemakers with significant remaining battery life are potentially life-saving devices for people in low- and middle-income countries (LMICs). [97] The Institute of Medicine, a US non-governmental organization, has reported that inadequate access to advanced cardiovascular technologies is a major contributor to cardiovascular disease morbidity and mortality in LMICs. Ever since the 1970s, multiple studies worldwide have reported on the safety and efficacy of pacemaker reuse. As of 2016, widely acceptable standards for safe pacemaker and ICD reuse had not been developed, and there continued to be legal and regulatory barriers to widespread adoption of medical device reuse. [98]

Manufacturers

Current and prior manufacturers of implantable pacemakers

See also

Related Research Articles

<span class="mw-page-title-main">Electrocardiography</span> Examination of the hearts electrical activity

Electrocardiography is the process of producing an electrocardiogram, a recording of the heart's electrical activity through repeated cardiac cycles. It is an electrogram of the heart which is a graph of voltage versus time of the electrical activity of the heart using electrodes placed on the skin. These electrodes detect the small electrical changes that are a consequence of cardiac muscle depolarization followed by repolarization during each cardiac cycle (heartbeat). Changes in the normal ECG pattern occur in numerous cardiac abnormalities, including:

<span class="mw-page-title-main">Cardioversion</span> Conversion of a cardiac arrhythmia to a normal rhythm using an electrical shock or medications

Cardioversion is a medical procedure by which an abnormally fast heart rate (tachycardia) or other cardiac arrhythmia is converted to a normal rhythm using electricity or drugs.

<span class="mw-page-title-main">Defibrillation</span> Treatment for life-threatening cardiac arrhythmias

Defibrillation is a treatment for life-threatening cardiac arrhythmias, specifically ventricular fibrillation (V-Fib) and non-perfusing ventricular tachycardia (V-Tach). A defibrillator delivers a dose of electric current to the heart. Although not fully understood, this process depolarizes a large amount of the heart muscle, ending the arrhythmia. Subsequently, the body's natural pacemaker in the sinoatrial node of the heart is able to re-establish normal sinus rhythm. A heart which is in asystole (flatline) cannot be restarted by a defibrillator; it would be treated only by cardiopulmonary resuscitation (CPR) and medication, and then by cardioversion or defibrillation if it converts into a shockable rhythm.

<span class="mw-page-title-main">Implantable cardioverter-defibrillator</span> Medical device

An implantable cardioverter-defibrillator (ICD) or automated implantable cardioverter defibrillator (AICD) is a device implantable inside the body, able to perform defibrillation, and depending on the type, cardioversion and pacing of the heart. The ICD is the first-line treatment and prophylactic therapy for patients at risk for sudden cardiac death due to ventricular fibrillation and ventricular tachycardia.

<span class="mw-page-title-main">Third-degree atrioventricular block</span> Medical condition

Third-degree atrioventricular block is a medical condition in which the electrical impulse generated in the sinoatrial node in the atrium of the heart can not propagate to the ventricles.

<span class="mw-page-title-main">Short QT syndrome</span> Medical condition

Short QT syndrome (SQT) is a very rare genetic disease of the electrical system of the heart, and is associated with an increased risk of abnormal heart rhythms and sudden cardiac death. The syndrome gets its name from a characteristic feature seen on an electrocardiogram (ECG) – a shortening of the QT interval. It is caused by mutations in genes encoding ion channels that shorten the cardiac action potential, and appears to be inherited in an autosomal dominant pattern. The condition is diagnosed using a 12-lead ECG. Short QT syndrome can be treated using an implantable cardioverter-defibrillator or medications including quinidine. Short QT syndrome was first described in 2000, and the first genetic mutation associated with the condition was identified in 2004.

<span class="mw-page-title-main">Ventricular tachycardia</span> Abnormally fast rhythm of the hearts ventricles

Ventricular tachycardia is a cardiovascular disorder in which fast heart rate occurs in the ventricles of the heart. Although a few seconds of VT may not result in permanent problems, longer periods are dangerous; and multiple episodes over a short period of time are referred to as an electrical storm. Short periods may occur without symptoms, or present with lightheadedness, palpitations, shortness of breath, chest pain, and decreased level of consciousness. Ventricular tachycardia may lead to coma and persistent vegetative state due to lack of blood and oxygen to the brain. Ventricular tachycardia may result in ventricular fibrillation (VF) and turn into cardiac arrest. This conversion of the VT into VF is called the degeneration of the VT. It is found initially in about 7% of people in cardiac arrest.

<span class="mw-page-title-main">Supraventricular tachycardia</span> Abnormally fast heart rhythm

Supraventricular tachycardia (SVT) is an umbrella term for fast heart rhythms arising from the upper part of the heart. This is in contrast to the other group of fast heart rhythms – ventricular tachycardia, which start within the lower chambers of the heart. There are four main types of SVT: atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia (PSVT), and Wolff–Parkinson–White syndrome. The symptoms of SVT include palpitations, feeling of faintness, sweating, shortness of breath, and/or chest pain.

Clinical cardiac electrophysiology, is a branch of the medical specialty of cardiology concerned with the study and treatment of rhythm disorders of the heart. Cardiologists with expertise in this area are usually referred to as electrophysiologists. Electrophysiologists are trained in the mechanism, function, and performance of the electrical activities of the heart. Electrophysiologists work closely with other cardiologists and cardiac surgeons to assist or guide therapy for heart rhythm disturbances (arrhythmias). They are trained to perform interventional and surgical procedures to treat cardiac arrhythmia.

<span class="mw-page-title-main">Transcutaneous pacing</span> Method of temporary stabilizing an individuals heartbeat

Transcutaneous pacing (TCP), also called external pacing, is a temporary means of pacing a patient's heart during a medical emergency. It should not be confused with defibrillation using a manual or automatic defibrillator, though some newer defibrillators can do both, and pads and an electrical stimulus to the heart are used in transcutaneous pacing and defibrillation. Transcutaneous pacing is accomplished by delivering pulses of electric current through the patient's chest, which stimulates the heart to contract.

<span class="mw-page-title-main">Michel Haïssaguerre</span>

Michel Haïssaguerre is a French cardiologist and electrophysiologist. His investigations have been the basis for development of new markers and therapies for atrial and ventricular fibrillation.

Morton Maimon Mower was an American cardiologist specializing in electrophysiology and the co-inventor of the automatic implantable cardioverter defibrillator. He served in several professional capacities at Sinai Hospital and Cardiac Pacemakers Inc. In 1996, he became the chairman and chief executive officer of Mower Research Associates. He was inducted into the National Inventors Hall of Fame in 2002 for the development of the automatic implantable cardioverter defibrillator with Michel Mirowski in the 1970s. He continued his research in the biomechanical engineering laboratories at Johns Hopkins University.

<span class="mw-page-title-main">Pacemaker syndrome</span> Medical condition

Pacemaker syndrome is a condition that represents the clinical consequences of suboptimal atrioventricular (AV) synchrony or AV dyssynchrony, regardless of the pacing mode, after pacemaker implantation. It is an iatrogenic disease—an adverse effect resulting from medical treatment—that is often underdiagnosed. In general, the symptoms of the syndrome are a combination of decreased cardiac output, loss of atrial contribution to ventricular filling, loss of total peripheral resistance response, and nonphysiologic pressure waves.

<span class="mw-page-title-main">Cardiac resynchronization therapy</span> Treatment for heart failure

Cardiac resynchronisation therapy is the insertion of electrodes in the left and right ventricles of the heart, as well as on occasion the right atrium, to treat heart failure by coordinating the function of the left and right ventricles via a pacemaker, a small device inserted into the anterior chest wall.

Pacemaker failure is the inability of an implanted artificial pacemaker to perform its intended function of regulating the beating of the heart. A pacemaker uses electrical impulses delivered by electrodes in order to contract the heart muscles. Failure of a pacemaker is defined by the requirement of repeat surgical pacemaker-related procedures after the initial implantation. Most implanted pacemakers are dual chambered and have two leads, causing the implantation time to take longer because of this more complicated pacemaker system. These factors can contribute to an increased rate of complications which can lead to pacemaker failure.

A wearable cardioverter defibrillator (WCD) is a non-invasive, external device for patients at risk of sudden cardiac arrest (SCA). It allows physicians time to assess their patient's arrhythmic risk and see if their ejection fraction improves before determining the next steps in patient care. It is a leased device. A summary of the device, its technology and indications was published in 2017 and reviewed by the EHRA Scientific Documents Committee.

Cameron Health was a medical device developer based in San Clemente, California, US. Cameron Health had its European office, Cameron Health BV, in Arnhem, The Netherlands. The privately held company's focus was on a new generation of minimally invasive implantable cardioverter-defibrillator (ICD) which they called a Subcutaneous Implantable Defibrillator (S-ICD). Cameron Health's approach avoided implanting transvenous leads into the heart, which had been the usual procedure for cardiac devices. Instead, the Cameron ICD was entirely implanted outside the thoracic wall.

Cardiac contractility modulation is a therapy which is intended for the treatment of patients with moderate to severe heart failure with symptoms despite optimal medical therapy who can benefit from an improvement in cardiac output. The short- and long-term use of this therapy enhances the strength of ventricular contraction and therefore the heart's pumping capacity by modulating (adjusting) the myocardial contractility. This is provided by a pacemaker-like device that applies non-excitatory electrical signals adjusted to and synchronized with the electrical action in the cardiac cycle.

<span class="mw-page-title-main">Yaariv Khaykin</span> Canadian cardiologist

Yaariv Khaykin is a Canadian cardiologist and a clinical researcher in the area of electrophysiology. He is the director of the Newmarket Electrophysiology Research Group at the Southlake Regional Health Centre. He has published research into complex ablation and pioneered cardiac ablation methods.

<span class="mw-page-title-main">Subcutaneous implantable defibrillator</span>

Subcutaneous implantable cardioverter defibrillator, or S-ICD, is an implantable medical device for detecting and terminating ventricular tachycardia and ventricular fibrillation in patients at risk of sudden cardiac arrest. It is a type of implantable cardioverter defibrillator but unlike the transvenous ICD, the S-ICD lead is placed just under the skin, leaving the heart and veins untouched.

References

  1. ↑ "Devices@FDA". www.accessdata.fda.gov. Retrieved 2022-04-27.
  2. ↑ Product Performance Report – Cardiac Rhythm Management (PDF) (Report). St. Jude Medical. October 2008. Archived from the original (PDF) on 2022-08-19. Retrieved 2022-04-27.
  3. ↑ "UpToDate". www.uptodate.com. Retrieved 2022-08-02.
  4. ↑ "Pacemakers" . Retrieved 28 July 2022.
  5. ↑ "Overview of Pacemakers and Implantable Cardioverter Defibrillators (ICDs) – Health Encyclopedia – University of Rochester Medical Center". www.urmc.rochester.edu. Retrieved 2022-08-02.
  6. ↑ "Biventricular Pacemaker". Cleveland Clinic. Retrieved 2022-08-02.
  7. ↑ Eich C, Bleckmann A, Paul T (October 2005). "Percussion pacing in a three-year-old girl with complete heart block during cardiac catheterization". Br J Anaesth. 95 (4): 465–7. doi: 10.1093/bja/aei209 . PMID   16051649.
  8. ↑ Shah, Maully; Rhodes, Larry; Kaltman, Jonathan (2017-03-20). Cardiac Pacing and Defibrillation in Pediatric and Congenital Heart Disease. John Wiley & Sons. ISBN   978-0-470-67109-2.
  9. ↑ Valchanov, Kamen; Jones, Nicola; Hogue, Charles W. (2018). Core Topics in Cardiothoracic Critical Care. Cambridge University Press. ISBN   978-1-108-66567-4.[ page needed ]
  10. 1 2 3 4 5 "Pacemakers, Patient and Public Information Center : Heart Rhythm Society". Archived from the original on 2010-06-19.
  11. 1 2 "The leadless pacemaker: A new era in cardiac pacing". Hospital Healthcare Europe. Archived from the original on 2019-02-02. Retrieved 2019-02-01.
  12. ↑ Bernstein AD, Daubert JC, Fletcher RD, Hayes DL, Lüderitz B, Reynolds DW, Schoenfeld MH, Sutton R (2002). "The revised NASPE/BPEG generic code for antibradycardia, adaptive-rate, and multisite pacing. North American Society of Pacing and Electrophysiology/British Pacing and Electrophysiology Group". Pacing Clin Electrophysiol. 25 (2): 260–4. doi:10.1046/j.1460-9592.2002.00260.x. PMID   11916002. S2CID   12887364.
  13. ↑ Böhm A, Pintér A, Székely A, Préda I (1998). "Clinical Observations with Long-term Atrial Pacing". Pacing Clin Electrophysiol. 21 (1): 246–9. doi:10.1111/j.1540-8159.1998.tb01097.x. PMID   9474681. S2CID   23277568.
  14. ↑ Crick JC (1991). "European Multicenter Prospective Follow-Up Study of 1,002 Implants of a Single Lead VDD Pacing System". Pacing Clin Electrophysiol. 14 (11): 1742–4. doi:10.1111/j.1540-8159.1991.tb02757.x. PMID   1749727. S2CID   698053.
  15. ↑ Dubin, Dale (2000). Rapid Interpretation of EKG's: An Interactive Course. Cover Publishing Company. ISBN   978-0-912912-06-6.
  16. ↑ "UpToDate". www.uptodate.com. Retrieved 2018-09-10.
  17. ↑ Baltazar, Romulo F. (2012-03-28). Basic and Bedside Electrocardiography. Lippincott Williams & Wilkins. ISBN   978-1-4511-4791-9.
  18. ↑ Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L (2005). "The effect of cardiac resynchronization on morbidity and mortality in heart failure" (PDF). N. Engl. J. Med. 352 (15): 1539–49. doi:10.1056/NEJMoa050496. PMID   15753115. S2CID   13938919.
  19. ↑ Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH (2005). "Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure". N. Engl. J. Med. 352 (3): 225–37. doi: 10.1056/NEJMoa043399 . PMID   15659722. S2CID   19118406.
  20. ↑ Ganjehei L, Razavi M, Massumi A (2011). "Cardiac resynchronization therapy: a decade of experience and the dilemma of nonresponders". Texas Heart Institute Journal. 38 (4): 358–60. PMC   3147217 . PMID   21841860.
  21. ↑ Sharma, Parikshit S.; Vijayaraman, Pugazhendhi; Ellenbogen, Kenneth A. (2020). "Permanent His bundle pacing: shaping the future of physiological ventricular pacing". Nature Reviews Cardiology. 17 (1): 22–36. doi:10.1038/s41569-019-0224-z. PMID   31249403. S2CID   195698761.
  22. ↑ "Focus on Electrophysiology: His Bundle Pacing: A More Physiologic Alternative For Pacing". American College of Cardiology. April 26, 2019.
  23. ↑ "Anthony Francis Rickards". Heart. 90 (9): 981–2. 2004. doi:10.1136/hrt.2004.045674. PMC   1768450 .
  24. ↑ Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, Kutalek SP, Sharma A (December 2002). "Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial". JAMA. 288 (24): 3115–23. doi: 10.1001/jama.288.24.3115 . PMID   12495391.
  25. 1 2 3 4 5 Ramsdale, David R. (2012). Cardiac pacing and device therapy. Rao, Archana. London: Springer. ISBN   978-1-4471-2939-4. OCLC   822576869.
  26. ↑ Pena, Rafael E.; Shepard, Richard K.; Ellenbogen, Kenneth A. (December 2006). "How to Make a Submuscular Pocket". Journal of Cardiovascular Electrophysiology. 17 (12): 1381–1383. doi: 10.1111/j.1540-8167.2006.00665.x . PMID   17081202. S2CID   38032736.
  27. ↑ Beinart, R; Nazarian, S (24 December 2013). "Effects of external electrical and magnetic fields on pacemakers and defibrillators: from engineering principles to clinical practice". Circulation. 128 (25): 2799–809. doi: 10.1161/CIRCULATIONAHA.113.005697 . PMC   3908865 . PMID   24366589.
  28. ↑ Marco D, Eisinger G, Hayes DL (November 1992). "Testing of work environments for electromagnetic interference". Pacing Clin Electrophysiol. 15 (11 Pt 2): 2016–22. doi:10.1111/j.1540-8159.1992.tb03013.x. PMID   1279591. S2CID   24234010.
  29. ↑ Maass, A. H.; Hemels, M. E. W.; Allaart, C. P. (December 2018). "Magnetic resonance imaging in patients with cardiac implantable electronic devices". Netherlands Heart Journal. 26 (12): 584–590. doi:10.1007/s12471-018-1192-3. PMC   6288036 . PMID   30406601.
  30. ↑ "Revo MRI SureScan Pacing System - P090013". U.S. Food and Drug Administration - Medical Device Approvals and Clearances. 24 February 2011. Archived from the original on 20 October 2012.
  31. ↑ "Terminology". Magnetic Resonance Safety Testing Services. Archived from the original on 11 October 2013. Retrieved 13 February 2023.
  32. ↑ Husten, Larry. "FDA Approves Second Generation MRI-Friendly Pacemaker System From Medtronic". Forbes, 2013-02-13.
  33. ↑ "For physicians: V: Select and save MRI settings; VII: Disable MRI settings" (PDF). MRI-Ready Systems Manual - MRI Procedure Information for the MR Conditional System (Report). St. Jude Medical. 2016.
  34. ↑ Ferreira, António M; Costa, Francisco; Tralhão, António; Marques, Hugo; Cardim, Nuno; Adragão, Pedro (7 May 2014). "MRI-conditional pacemakers: current perspectives". Medical Devices: Evidence and Research. 7: 115–124. doi: 10.2147/MDER.S44063 . PMC   4019608 . PMID   24851058.
  35. ↑ "MP3 Headphones Interfere With Implantable Defibrillators, Pacemakers – Beth Israel Deaconess Medical Center". www.bidmc.org. Archived from the original on 2010-09-27. Retrieved 2008-11-10.
  36. ↑ "What is a pacemaker?". HRMReview. Archived from the original on 22 May 2014. Retrieved 22 May 2014.
  37. ↑ Irnich, Werner; Bernstein, Alan D. (May 2006). "Do induction cooktops interfere with cardiac pacemakers?". EP Europace. 8 (5): 377–384. doi:10.1093/europace/eul014. PMID   16635999.
  38. ↑ Baddour, Larry M.; Epstein, Andrew E.; Erickson, Christopher C.; Knight, Bradley P.; Levison, Matthew E.; Lockhart, Peter B.; Masoudi, Frederick A.; Okum, Eric J.; Wilson, Walter R.; Beerman, Lee B.; Bolger, Ann F.; Estes, N.A. Mark; Gewitz, Michael; Newburger, Jane W.; Schron, Eleanor B.; Taubert, Kathryn A. (26 January 2010). "Update on Cardiovascular Implantable Electronic Device Infections and Their Management". Circulation. 121 (3): 458–477. doi: 10.1161/circulationaha.109.192665 . PMID   20048212.
  39. ↑ "Heart devices can be turned off near end of life". amednews.com. May 31, 2010. Archived from the original on Oct 24, 2017.
  40. ↑ "End of Life and Heart Rhythm Devices". Heart Rhythm Society. 2014. Archived from the original on Oct 23, 2023.
  41. ↑ Butler, Katy (18 June 2010). "What Broke My Father's Heart" . The New York Times. Archived from the original on Apr 2, 2024.
  42. 1 2 Halperin, Daniel; Thomas S. Heydt-Benjamin; Benjamin Ransford; Shane S. Clark; Benessa Defend; Will Morgan; Kevin Fu; Tadayoshi Kohno; William H. Maisel (May 2008). Pacemakers and Implantable Cardiac Defibrillators: Software Radio Attacks and Zero-Power Defenses (PDF). IEEE Symposium on Security and Privacy. Retrieved 2008-08-10– via Archimedes Center for Medical Device Security.
  43. ↑ Goldman, Jeff (2012-04-20). "Researchers Develop Personal Firewall Solution for Pacemakers, Insulin Pumps". eSecurity Planet. Archived from the original on Apr 23, 2012. Retrieved 2012-04-20.
  44. ↑ Smith, Ben (26 August 2014). "UOTW #15". Ultrasound of the Week. Archived from the original on Nov 6, 2018. Retrieved 27 May 2017.{{cite web}}: CS1 maint: unfit URL (link)
  45. ↑ "Risks – Pacemaker". Mayo Clinic. Archived from the original on Feb 18, 2017. Retrieved 2016-12-01.
  46. 1 2 Pacemaker-Mediated Tachycardia at eMedicine
  47. ↑ Love, Charles J. (2011). "Pacemaker Troubleshooting and Follow-up". Clinical Cardiac Pacing, Defibrillation and Resynchronization Therapy. pp. 844–888. doi:10.1016/B978-1-4377-1616-0.00029-1. ISBN   978-1-4377-1616-0.
  48. ↑ Kamalvand, Kayvan; Tan, Kim; Kotsakis, Athanasios; Bucknall, Cliff; Sulke, Neil (August 1997). "Is Mode Switching Beneficial? A Randomized Study in Patients With Paroxysmal Atrial Tachyarrhythmias". Journal of the American College of Cardiology. 30 (2): 496–504. doi:10.1016/S0735-1097(97)00162-9. PMID   9247524. S2CID   23092273.
  49. ↑ Noheria, Amit; DeSimone, Christopher V.; Asirvatham, Samuel J. (November 2018). "Cardiac Implantable Electronic Device Lead Thrombus as a Nidus for Pulmonary and Systemic Embolization". JACC: Clinical Electrophysiology. 4 (11): 1437–1439. doi: 10.1016/j.jacep.2018.08.019 . PMID   30466849.
  50. ↑ Santomauro, M.; Costanzo, A.; Ottaviano, L.; Cresta, R.; Minichiello, S.; Prastaro, M.; Chiariello, M. (2000). "Pacemaker/ICD Patients: To Anticoagulate or Not to Anticoagulate?". Cardiac Arrhythmias 1999 - Vol.1. pp. 494–500. doi:10.1007/978-88-470-2139-6_66. ISBN   978-88-470-0071-1.
  51. ↑ Lin, Grace; Nishimura, Rick A.; Connolly, Heidi M.; Dearani, Joseph A.; Sundt, Thoralf M.; Hayes, David L. (May 2005). "Severe Symptomatic Tricuspid Valve Regurgitation Due to Permanent Pacemaker or Implantable Cardioverter-Defibrillator Leads". Journal of the American College of Cardiology. 45 (10): 1672–1675. doi: 10.1016/j.jacc.2005.02.037 . PMID   15893186.
  52. ↑ Wilkoff, Bruce L.; Love, Charles J.; Byrd, Charles L.; Bongiorni, Maria Grazia; Carrillo, Roger G.; Crossley, George H.; Epstein, Laurence M.; Friedman, Richard A.; Kennergren, Charles E.H.; Mitkowski, Przemyslaw; Schaerf, Raymond H.M.; Wazni, Oussama M. (July 2009). "Transvenous Lead Extraction: Heart Rhythm Society Expert Consensus on Facilities, Training, Indications, and Patient Management". Heart Rhythm. 6 (7): 1085–1104. doi:10.1016/j.hrthm.2009.05.020. PMID   19560098.
  53. ↑ "What is Laser-Assisted Lead Extraction? | DFW". HeartPlace. Archived from the original on 2022-09-20. Retrieved 2022-09-16.
  54. ↑ Gaca, Jeffrey G.; Lima, Brian; Milano, Carmelo A.; Lin, Shu S.; Davis, R. Duane; Lowe, James E.; Smith, Peter K. (May 2009). "Laser-Assisted Extraction of Pacemaker and Defibrillator Leads: The Role of the Cardiac Surgeon". The Annals of Thoracic Surgery. 87 (5): 1446–1451. doi:10.1016/j.athoracsur.2009.02.015. PMID   19379883.
  55. ↑ Kalavakunta, Jagadeesh Kumar; Gupta, Vishal; Paulus, Basil; Lapenna, William (2014). "An Unusual Cause of Transient Ischemic Attack in a Patient with Pacemaker". Case Reports in Cardiology. 2014: 265759. doi: 10.1155/2014/265759 . PMC   4008350 . PMID   24826308.
  56. ↑ Brunner, M (January 2004). "Long-term survival after pacemaker implantation Prognostic importance of gender and baseline patient characteristics". European Heart Journal. 25 (1): 88–95. doi: 10.1016/j.ehj.2003.10.022 . PMID   14683747.
  57. 1 2 Bernstein, Alan D.; Camm, A. John; Fisher, John D.; Fletcher, Ross D.; Mead, R. Hardwin; Nathan, Anthony W.; Parsonnet, Victor; Rickards, Anthony F.; Smyth, Nicholas P.D.; Sutton, Richard; Tarjan, Peter P. (September 1993). "The NASPE */BPEG ** Defibrillator Code". Pacing and Clinical Electrophysiology. 16 (9): 1776–1780. doi:10.1111/j.1540-8159.1993.tb01809.x. PMID   7692407.
  58. ↑ McWilliam JA (1889). "Electrical stimulation of the heart in man". Br Med J. 1 (1468): 348–50. doi:10.1136/bmj.1.1468.348. PMC   2154721 . PMID   20752595.
  59. ↑ Rhodes, Larry; Campbell, Robert (2017). "History of cardiac pacing and defibrillation in the young". Cardiac Pacing and Defibrillation in Pediatric and Congenital Heart Disease. pp. 1–11. doi:10.1002/9781119333050.ch1. ISBN   978-0-470-67109-2.
  60. ↑ Lidwell M C, "Cardiac Disease in Relation to Anaesthesia" in Transactions of the Third Session, Australasian Medical Congress, Sydney, Australia, Sept. 2–7, 1929, p. 160.
  61. 1 2 Mond HG, Sloman JG, Edwards RH (1982). "The first pacemaker". Pacing and Clinical Electrophysiology. 5 (2): 278–82. doi:10.1111/j.1540-8159.1982.tb02226.x. PMID   6176970. S2CID   22049678.
  62. ↑ Aquilina, O (2006). "A brief history of cardiac pacing". Images in Paediatric Cardiology. 8 (2): 17–81. PMC   3232561 . PMID   22368662.
  63. ↑ Furman S, Szarka G, Layvand D (2005). "Reconstruction of Hyman's second pacemaker". Pacing Clin Electrophysiol. 28 (5): 446–53. doi:10.1111/j.1540-8159.2005.09542.x. PMID   15869680. S2CID   29138993.
  64. ↑ Kidder, David S.; Oppenheim, Noah D.; Young, Bruce K. (2009-10-13). The Intellectual Devotional: Health: Revive Your Mind, Complete Your Education, and Digest a Daily Dose of Wellness Wisdom. Harmony/Rodale. ISBN   978-1-60529-330-1.
  65. ↑ "John Alexander Hopps fonds". Archival description. Library and Archives Canada. 2008-03-19. Archived from the original on 2020-07-28. Retrieved 16 Sep 2016.
  66. ↑ "IEEE Milestone in Electrical Engineering and Computing". Archived from the original on February 25, 2021. Retrieved September 5, 2009.
  67. ↑ Silva, Regis A. de (2013-01-24). Heart Disease. ABC-CLIO. ISBN   978-0-313-37607-8.
  68. ↑ "Paul Maurice Zoll". Harvard Gazette. 19 April 2001.
  69. ↑ Weirich WL, Gott VL, Lillehei CW (1957). "The treatment of complete heart block by the combined use of a myocardial electrode and an artificial pacemaker". Surg Forum. 8: 360–3. PMID   13529629.
  70. ↑ Reynolds, Jorge (March 1988). "The Early History of Cardiac Pacing in Colombia". Pacing and Clinical Electrophysiology. 11 (3): 355–361. doi:10.1111/j.1540-8159.1988.tb05018.x. PMID   2452427. S2CID   20374411.
  71. ↑ Jeffrey, Kirk; Parsonnet, Victor (19 May 1998). "Cardiac Pacing, 1960–1985". Circulation: An American Heart Association Journal. 97 (19): 1978–1991. doi: 10.1161/01.CIR.97.19.1978 . PMID   9609092.
  72. ↑ "Gunning, Alfred James – Biographical entry – Plarr's Lives of the Fellows Online". Livesonline.rcseng.ac.uk. Retrieved 2013-12-29.
  73. ↑ "Our history". Nuffield Department of Surgical Sciences. University of Oxford. Retrieved 26 October 2020.
  74. ↑ "British Cardiovascular Society". Bcs.com. Archived from the original on 2013-12-12. Retrieved 2013-12-29.
  75. ↑ Record, C O; Sleight, P; Gunning, A J; Kenworthy-Browne, J M; Richings, M (1 November 1971). "Treatment of chronic heart block with the Lucas induction coil pacemaker". Heart. 33 (6): 938–942. doi:10.1136/hrt.33.6.938. PMC   458452 . PMID   5120241.
  76. ↑ Tesler, Ugo Filippo (2020). A History of Cardiac Surgery: An Adventurous Voyage from Antiquity to the Artificial Heart. Cambridge Scholars Publishing. p. 151. ISBN   978-1-5275-4480-2.
  77. ↑ Altman, Lawrence (18 Jan 2002). "Arne H. W. Larsson, 86; Had First Internal Pacemaker". New York Times. Retrieved 3 March 2014.
  78. ↑ Furman S, Schwedel JB (1959). "An intracardiac pacemaker for Stokes-Adams seizures". N. Engl. J. Med. 261 (5): 943–8. doi:10.1056/NEJM195911052611904. PMID   13825713.
  79. ↑ Parsonnet V (1978). "Permanent transvenous pacing in 1962". Pacing Clin Electrophysiol. 1 (2): 265–8. doi:10.1111/j.1540-8159.1978.tb03472.x. PMID   83641. S2CID   12263609.
  80. ↑ Parsonnet V, Zucker IR, Asa MM (1962). "Preliminary Investigation of the Development of a Permanent Implantable Pacemaker Using an Intracardiac Dipolar Electrode". Clin. Res. 10: 391.
  81. ↑ Parsonnet V, Zucker IR, Gilbert L, Asa M (1962). "An intracardiac bipolar electrode for interim treatment of complete heart block". Am. J. Cardiol. 10 (2): 261–5. doi:10.1016/0002-9149(62)90305-3. PMID   14484083.
  82. ↑ Lagergren H (1978). "How it happened: my recollection of early pacing". Pacing Clin Electrophysiol. 1 (1): 140–3. doi:10.1111/j.1540-8159.1978.tb03451.x. PMID   83610. S2CID   9118036.
  83. ↑ Lagergren H, Johansson L (1963). "Intracardiac stimulation for complete heart block". Acta Chirurgica Scandinavica. 125: 562–566. PMID   13928055.
  84. ↑ Jean Jacques Welti:Biography, Heart Rhythm Foundation[ full citation needed ]
  85. ↑ Blue Plaque Guide
  86. ↑ "University of Birmingham". bhamalumni.org. Archived from the original on 2014-10-06.
  87. 1 2 US 3822707,Adducci, Anthony J.&Schwalm, Arthur W.,"Metal-enclosed cardiac pacer with solid-state power source",published 1974-07-09,issued 1972-04-17, assigned to Cardiac Pacemekers Inc.
  88. ↑ "The History of Nuclear Powered Pacemakers". large.stanford.edu. Retrieved 2023-04-18.
  89. ↑ "Pioneers of the Medical Device Industry". Minnesota Historical Society.
  90. ↑ Dasmahapatra, H. K.; Jamieson, M. P.; Brewster, G. M.; Doig, B.; Pollock, J. C. (1986). "Permanent cardiac pacemaker in infants and children". The Thoracic and Cardiovascular Surgeon. 34 (4): 230–235. doi:10.1055/s-2007-1020418. PMID   2429390.
  91. ↑ "Doctors gave me a pacemaker when I was 11 days old". 17 January 2023.
  92. ↑ "Medtronic's Minimally Invasive Pacemaker the Size of a Multivitamin". Singularity Hub. 2013-12-27. Retrieved 2013-12-29.
  93. ↑ "European Post-Approval Trial for Nanostim". DAIC. 2014-03-18. Retrieved 2015-05-04.
  94. ↑ "First-in-Human Data". Medscape. Retrieved 2014-06-19.
  95. ↑ "Leadless Pacing from St. Jude Medical". Archived from the original on 2014-10-29.
  96. ↑ Stiles, Steve (24 March 2014). "New Data on Leadless Pacemaker Supports Efficacy, Safety". Medscape.
  97. ↑ Mazumdar, Tulip (2013-11-19). "British charity calls for re-use of pacemakers abroad". BBC News. Retrieved 2018-07-31.
  98. ↑ Crawford, TC; Eagle, KA (2017). "Reuse of cardiac implantable electronic devices to improve and extend lives: a call to action". Heart Asia. 9 (1): 34–35. doi:10.1136/heartasia-2016-010835. PMC   5278341 . PMID   28191825.
  99. ↑ "LivaNova closes $190 CRM sale to MicroPort". Mass Device. 30 April 2018.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.